MétaCan
Menu
Back to cohort
Record W4377969339 · doi:10.1016/j.kint.2023.05.009

Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

2023· review· en· W4377969339 on OpenAlexaff
Elaine Ku, Lucia Del Vecchio, Kai‐Uwe Eckardt, Volker H. Haase, Kirsten L. Johansen, Masaomi Nangaku, Navdeep Tangri, Sushrut S. Waikar, Andrzej Więcek, Michael Cheung, Michel Jadoul, Wolfgang C. Winkelmayer­, David C. Wheeler, Barış Afşar, Tadao Akizawa, Stefan D. Anker, Mustafa Arıcı, Jodie L. Babitt, Jonathan Barratt, Jeffrey S. Berns, Anatole Besarab, Sunil Bhandari, Aleix Cases, Glenn M. Chertow, Cynthia Delgado, Tillman B. Drüeke, Steven Fishbane, Rafael Gómez, Morgan E. Grams, Takayuki Hamano, Chuan‐Ming Hao, Raymond K. Hsu, Kunitoshi Iseki, Isabelle Jordans, Edgar V. Lerma, Francesco Locatelli, Iain C. Macdougall, Jolanta Małyszko, Patrick H. Maxwell, Lawrence P. McMahon, Gregorio T. Obrador, Marlies Ostermann, Roberto Pecoits‐Filho, Farzana Perwad, Simon D. Roger, Ajay Singh, Laura Solá, Bruce Spinowitz, Mai Sugahara, Toshiyuki Takahashi, Mototsugu TANAKA, Tetsuhiro Tanaka, Der‐Cherng Tarng, Marcello Tonelli, Yusuke Tsukamoto, Carl P. Walther, Angela Yee‐Moon Wang, Hong Kong, Bradley A. Warady, Angela C Webster, Matthew R. Weir, Jay B. Wish, Muh Geot Wong

Bibliographic record

VenueKidney International · 2023
Typereview
Languageen
FieldMedicine
TopicErythropoietin and Anemia Treatment
Canadian institutionsUniversity of ManitobaSeven Oaks General Hospital
FundersNational Institute of Diabetes and Digestive and Kidney DiseasesAkebia TherapeuticsAstellas PharmaTorii PharmaceuticalMitsubishi Tanabe Pharma CorporationFresenius Medical Care North AmericaAstraZenecaGlaxoSmithKlineAmgenU.S. Department of Veterans Affairs
KeywordsMedicineKidney diseaseAnemiaIntensive care medicineGuidelineDiseaseAdverse effectInternal medicinePathology

Abstract

fetched live from OpenAlex

Anemia is common in patients with chronic kidney disease and is associated with a high burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline for the diagnosis and management of anemia in chronic kidney disease. Since then, new data from studies assessing established and emerging therapies for the treatment of anemia and iron deficiency have become available. Beginning in 2019, KDIGO planned 2 Controversies Conferences to review the new evidence and its potential impact on the management of anemia in clinical practice. Here, we report on the second of these conferences held virtually in December 2021, which focused on a new class of agents-the hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs). This report provides a review of the consensus points and controversies from this second conference and highlights areas that warrant prioritization for future research.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.004
Threshold uncertainty score0.023

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.003
Bibliometrics0.0030.003
Science and technology studies0.0000.000
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.044
GPT teacher head0.354
Teacher spread0.310 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations136
Published2023
Admission routes1
Has abstractno

Explore more

Same venueKidney InternationalSame topicErythropoietin and Anemia TreatmentFrench-language works237,207